Omnicell (NASDAQ:OMCL) Shares Gap Down – Here’s What Happened

Omnicell, Inc. (NASDAQ:OMCL)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $41.40, but opened at $35.54. Omnicell shares last traded at $36.8760, with a volume of 528,962 shares traded.

Key Omnicell News

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported second-quarter revenue of approximately $312 million, up 7% year over year, while earnings exceeded analyst expectations. Reported EPS figures varied by accounting measure and source, ranging from $0.52 GAAP to $0.94 under the Zacks presentation, versus a $0.48 consensus estimate. Omnicell Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year 2026 outlook for adjusted earnings, with EPS guidance of $2.15-$2.30 versus the $1.81 analyst consensus. Full-year revenue guidance was set at $1.225 billion-$1.245 billion, broadly in line with expectations. Omnicell Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability improved significantly from the prior year, supported by demand for connected devices, growth in technical services and software-as-a-service offerings, and cost controls. GAAP net income rose to $24 million from $6 million, and the company ended June with $292 million in cash and $168 million in debt. Omnicell Q2 2026 Revenue Rises 7 Percent
• Neutral Sentiment: Omnicell named Nnamdi Njoku president and chief operating officer effective July 1, adding a management transition for investors to monitor.
• Negative Sentiment: Third-quarter EPS guidance of $0.35-$0.43 was below the $0.43 consensus midpoint comparison, while revenue guidance of $301 million-$307 million was below the $312.6 million analyst estimate. The near-term outlook appears to be the main reason the stock is under pressure despite the second-quarter beat.
• Negative Sentiment: Recent insider activity has consisted entirely of reported sales, including transactions by CEO Randall Lipps and other executives, which may add to investor caution.

Analysts Set New Price Targets

A number of brokerages have commented on OMCL. KeyCorp increased their target price on Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Wells Fargo & Company upped their price objective on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $59.86.

Omnicell Trading Down 9.8%

The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 84.30, a price-to-earnings-growth ratio of 1.11 and a beta of 0.96. The business’s 50-day moving average price is $42.29 and its two-hundred day moving average price is $41.23.

Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. The firm had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. Omnicell’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.26 EPS. Equities analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Insider Activity

In other news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the transaction, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This represents a 1.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Institutional Trading of Omnicell

Several institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its holdings in shares of Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after buying an additional 137,834 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after acquiring an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC grew its position in Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after acquiring an additional 62,733 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after acquiring an additional 27,497 shares during the period. Finally, Geode Capital Management LLC increased its stake in Omnicell by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after acquiring an additional 11,424 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.